mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.006 |
mRNA |
OSI-027 |
CTRPv2 |
pan-cancer |
AAC |
-0.098 |
0.007 |
mRNA |
selumetinib:MK-2206 (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.099 |
0.007 |
mRNA |
tigecycline |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.007 |
mRNA |
decitabine:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.078 |
0.007 |
mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.087 |
0.007 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.097 |
0.007 |
mRNA |
TPCA-1 |
CTRPv2 |
pan-cancer |
AAC |
-0.089 |
0.007 |
mRNA |
lenvatinib |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.008 |
mRNA |
WZ8040 |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.008 |